UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Using an educational intervention to assess and improve disease‐specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-03, Vol.27 (2), p.229-236

2021

Volltextzugriff (PDF)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Thrombosis and haemostasis, 2021-08, Vol.121 (8), p.1079-1086

2021

Volltextzugriff (PDF)

Hemophilia: A Review of Perioperative Management for Cardiac Surgery

Journal of cardiothoracic and vascular anesthesia, 2022-01, Vol.36 (1), p.246-257

2022

Volltextzugriff (PDF)

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients

Journal of managed care & specialty pharmacy, 2020-10, Vol.26 (10), p.1258-1265

2020

Volltextzugriff (PDF)

Effects of PK‐guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2023-09, Vol.29 (5), p.1234-1242

2023

Volltextzugriff (PDF)

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

Journal of managed care & specialty pharmacy, 2020-04, Vol.26 (4), p.504-512

2020

Volltextzugriff (PDF)

The Authors Respond

Journal of managed care & specialty pharmacy, 2020-09, Vol.26 (9), p.1177-1178

2020

Volltextzugriff (PDF)

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors

Cochrane database of systematic reviews, 2017-09, Vol.9 (3), p.CD011441-CD011441

2017

Volltextzugriff (PDF)

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

Advances in therapy, 2020-06, Vol.37 (6), p.2763-2776

2020

Volltextzugriff (PDF)

Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults

Thrombosis research, 2011-04, Vol.127 (4), p.317-323

2011

Volltextzugriff (PDF)

Persistent aneurysmal vitelline vein with thrombus successfully managed with anticoagulation

Journal of pediatric surgery case reports, 2022-03, Vol.78, p.102179, Article 102179

2022

Volltextzugriff (PDF)

Management of joint bleeding in hemophilia

Expert Review of Hematology, 2012-08, Vol.5 (4), p.459-468

2012

Volltextzugriff (PDF)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

Research and practice in thrombosis and haemostasis, 2019-04, Vol.3 (2), p.268-276

2019

Volltextzugriff (PDF)

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

Journal of blood medicine, 2019-11, Vol.10, p.391-398

2019

Volltextzugriff (PDF)

Fibrinogen Replacement Underutilization in ECMO

Blood, 2020-11, Vol.136 (Supplement 1), p.4-5

2020

Volltextzugriff (PDF)

Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII

Blood, 2020-11, Vol.136 (Supplement 1), p.6-7

2020

Volltextzugriff (PDF)

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

The New England journal of medicine, 2016-05, Vol.374 (21), p.2054-2064

2016

Volltextzugriff (PDF)

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

Blood, 2018-11, Vol.132 (Supplement 1), p.1189-1189

2018

Volltextzugriff (PDF)

Recognition and Management of Hemophilia Emergencies

Clinical pediatric emergency medicine, 2011-09, Vol.12 (3), p.224-232

2011

Volltextzugriff (PDF)

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

Current medical research and opinion, 2022-07, Vol.38 (7), p.1133-1139

2022

Volltextzugriff (PDF)

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

Blood, 2023-11, Vol.142 (Supplement 1), p.506-506

2023

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII

Acta haematologica, 2024-04, p.1-10

2024

Volltextzugriff (PDF)

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A

The New England journal of medicine, 2024-07, Vol.391 (3), p.235-246

2024

Volltextzugriff (PDF)

Vitamin D Deficiency and Osteoporosis In Hemophilia: An Underappreciated Risk

Blood, 2013-11, Vol.122 (21), p.3593-3593

2013

Volltextzugriff (PDF)

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Blood, 2020-11, Vol.136 (Supplement 1), p.39-40

2020

Volltextzugriff (PDF)

1 – 25 von 52

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(52)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Using an educational intervention to assess and improve disease‐specific knowledge and health literacy and numeracy in adolescents and young adults with haemophilia A and B

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

Hemophilia: A Review of Perioperative Management for Cardiac Surgery

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients

Effects of PK‐guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

The Authors Respond

Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors

Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis

Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adults

Persistent aneurysmal vitelline vein with thrombus successfully managed with anticoagulation

Management of joint bleeding in hemophilia

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

Population Pharmacokinetic Modeling Of On-Demand And Surgical Use Of Nonacog Beta Pegol (N9-GP) And rFIXFc Based Upon The paradigm 7 Comparative Pharmacokinetic Study

Fibrinogen Replacement Underutilization in ECMO

Improved Bleeding Outcomes in Patients Who Switched From Sucrose-Formulated rFVIII to BAY 94-9027 Prophylaxis in PROTECT VIII

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

Recognition and Management of Hemophilia Emergencies

Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A

Once-Weekly Efanesoctocog Alfa Prophylaxis Provided High Sustained Factor VIII Activity Levels, Independent of Blood Group, in Children <12 Years of Age with Severe Hemophilia A

Long-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12–<18 Years at Enrolment into PROTECT VIII

Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A

Vitamin D Deficiency and Osteoporosis In Hemophilia: An Underappreciated Risk

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Association between Family History and Age of Diagnosis

Suchergebnisse filtern